Merck✓

Today, we presented late-breaking Phase 3 data in certain patients with advanced or recurrent #EndometrialCancer. We remain committed to advancing treatment options that can address unmet needs for those living with this disease. Learn more:

Today, we announced findings from our Phase 3 trial evaluating our investigational TROP2-directed antibody-drug conjugate (ADC) in certain patients with endometrial cancer. The results were presented for the first time during a Presidential Symposium at ESMO.

We announced positive Phase 3 data for our investigational individualized neoantigen therapy in combination with our company’s immunotherapy for patients with completely resected stage IIB-IV #melanoma in collaboration with @moderna_tx. Read more:

Today, the European Commission approved a combination regimen for adults with muscle-invasive #BladderCancer (MIBC). Learn more about how we're helping advance cancer care with Pfizer and Astellas:

We’re presenting new data from our industry-leading #oncology pipeline and portfolio at this year’s ESMO Congress, including three presentations from pivotal Phase 3 trials in Presidential Symposia. Learn more about our commitment to advancing research across a range of cancer types:

Today at #AAO2026, we’re presenting data from our Phase 2b/3 trial of an investigational drug in patients with diabetic macular edema (DME). Learn more:

Today we shared positive Phase 2b results evaluating our investigational anti-TL1A biologic in adults with moderate to severe hidradenitis suppurativa (HS). Learn more:

Learn more about our latest update in #oncology:

In collaboration with @EisaiUS, we’re proud to announce today’s #FDA approval of a new combination treatment option for certain patients with advanced renal cell carcinoma, marking an important step forward for people living with #KidneyCancer. Learn more:

Today, we announced Phase 2b/3 topline results for our investigational therapy in patients with #DiabeticMacularEdema (DME). This important milestone reflects our ongoing commitment to advancing research in #ophthalmology. Learn more:

Today, the FDA approved an updated label for a treatment option for adults living with pulmonary arterial hypertension (#PAH). Read more:

Learn more about our latest update in #oncology:

Today, we announced a positive CHMP opinion for a combination treatment regimen for adults with resectable muscle-invasive #BladderCancer (MIBC) in the European Union. Read more:

In collaboration with @moderna_tx, we’re excited to share the first positive Phase 3 topline results for our investigational individualized neoantigen therapy (INT) in combination with our company’s immunotherapy in the adjuvant setting for certain patients with completely resected stage IIB-IV #melanoma:

We’re pleased to announce the FDA has accepted our filing related to #RSV disease. Learn more:

Join us today at 9 a.m. ET to learn more about our Q2 2026 #earnings: $MRK

Our Q2 2026 #earnings results are live: Swipe below for perspective from Chairman and CEO Rob Davis. $MRK

Today we announced our initial post-approval access plans for our investigational HIV pre-exposure prophylaxis (PrEP). We are accelerating our access planning to help ensure that, if approved by the regulatory agency, this HIV prevention option can quickly reach those who need it in low- and middle-income countries. Learn more:

We’re presenting new data at AIDS 2026, in collaboration with @GileadSciences, from our Phase 3 trials of an investigational, once-weekly oral #HIV treatment for adults with virologically suppressed HIV. Learn more:

Today, we’re proud to announce the U.S. FDA approved the first oral PCSK9 inhibitor, providing a new treatment option as an adjunct to diet and exercise for adults living with #hypercholesterolemia, or high LDL cholesterol (LDL-C). Learn more about our approval here: